Second Line Chemotherapy for Pancreatic Cancer.
10.4166/kjg.2011.57.4.207
- Author:
Jeong Youp PARK
1
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. sensass@yuhs.ac
- Publication Type:Review ; English Abstract
- Keywords:
Pancreatic Cancer;
Chemotherapy
- MeSH:
Antibodies, Monoclonal/therapeutic use;
Antineoplastic Agents/therapeutic use;
Camptothecin/therapeutic use;
Deoxycytidine/analogs & derivatives/therapeutic use;
Drug Therapy, Combination;
Fluorouracil/therapeutic use;
Humans;
Organoplatinum Compounds/therapeutic use;
Pancreatic Neoplasms/*drug therapy;
Taxoids/therapeutic use
- From:The Korean Journal of Gastroenterology
2011;57(4):207-212
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pancreatic cancer is a very lethal cancer. It is the 5th most common cause for cancer related mortality in Korea. Most of patients have unresectable pancreatic cancer, and systemic chemotherapy remains the only treatment option for them. Gemcitabine has been adopted as the standard first-line agent for advanced pancreatic cancer, but the progression free survival with gemcitabine is short. Many of patients need further treatment. We reviewed the clinical trials of second line chemotherapy for gemcitabine refractory pancreatic cancer and tried to show currently available treatment options.
